Share the QR code < / P > < p > with wechat scanning code to friends and circle of friends < / P > < p > < / P > < p > [Global Times global network reporter Zhao Jue Leng Shumei] the vaccination volume of 2 billion doses of new crown vaccine in China is close at hand, and the construction of immune barrier is expected to be completed in the near future. In this case, the recent emergence of delta mutant strains in many parts of the country has heated the topic of "whether to carry out enhanced needle vaccination". Zhang Yuntao, chief scientist and vice president of Sinopharm China biology, said in an interview with global times and other media on the 23rd that clinical studies conducted in China and the UAE showed that the safety of China's biological inactivated vaccine booster needle was good. After the realization of "all connections should be made" and the formation of immune barrier in China, intensive needle vaccination can be carried out at an optional time < p > according to Zhang Yuntao, Sinopharm China biological inactivated vaccine has recently completed the phase I / II clinical trial of intensive injection for people over the age of 18 and people aged 3-17 in China, and the three injection vaccine is vaccinated according to the procedures of 0, 28 and 56 days. The overall results showed that the vaccine was safe and well tolerated after 3 doses in people over 3 years old, and could induce strong antibody response. In addition, the enhanced Immunization Test of China's biological inactivated vaccine was also launched in the UAE in June this year, which also showed good safety. The results of immunogenicity are under monitoring < p > on December 30 last year, the new crown inactivated vaccine developed by Sinopharm China biological Beijing company was approved for listing with conditions, and then mass vaccination was carried out in China. It has been more than 6 months since the first batch of vaccinators completed the immunization procedure. Zhang Yuntao told the Global Times reporter that from the current data, regardless of the technical route adopted, the antibody level for COVID-19 vaccine will decline for about half a year. Based on various data, the antibody level in the body decreased six months after two injections of Chinese biological inactivated vaccine < p > as the first country in the world to carry out mass vaccination of new crown vaccine, Israel recently found that the protective efficacy of Pfizer vaccine has decreased significantly since early June. A study conducted by the Ministry of health according to the epidemic data from June 20 to July 17 showed that the effective rate of Pfizer vaccine in preventing delta variant virus infection decreased to 39%, but it still had good results in preventing hospitalization and severe diseases. The Department said that after a long time of vaccination, the protective effect of the vaccine gradually weakened regardless of the age of the vaccinator. At present, Israel has begun to vaccinate some people with booster injections < p > delta variant strain has become the main epidemic strain in many countries. In recent months, COVID-19 has imported imported delta strains from Guangzhou, Nanjing and Zhengzhou. Many studies have shown that the delta variant not only has stronger transmission power, but also affects the protective effect of the vaccine to a certain extent, which makes the vaccination strategies of various countries face new choices: should we give priority to strengthening vaccination or variant vaccine in the next step < p > Zhang Yuntao believes that under the condition of realizing "all connections" and forming an immune barrier in China, it should be a priority to choose an opportunity to carry out intensive needle vaccination for special people. Zhang Yuntao added that on the one hand, the special population should include the elderly over the age of 60. The previous phase I / II clinical trials showed that the immunogenicity of the elderly after vaccination was lower than that of other populations; On the other hand, employees in catering, aviation, express and other industries also belong to special groups and should be vaccinated < p > Zhang Yuntao also said that in the study of booster needle in the UAE, the interval between the second and third needles was more than 6 months. The longer interval resulted in a significant increase in the antibody level in the subjects, even 5-10 times, showing that the booster needle played an obvious role in preventing the infection of variant virus strains and preventing disease

, "laboratory data and some real-world studies have shown that China's biological inactivated vaccine is still effective for the mutant strains such as Delta," Zhang Yuntao told the Global Times reporter. China's biology has been closely observing the variation of COVID-19, and the development of inactivated vaccines for mutant strains and delta mutants in South Africa is under way. At present, the materials have been submitted to the regulatory authorities. In other technical routes, the research and development of recombinant protein vaccine and mRNA vaccine for mutant strains are also in progress < p > according to Zhang Yuntao, China biology adopts the method of replacing the strain to develop the variant vaccine. After the variant vaccine is approved for clinical research, China biology will first conduct safety evaluation, and then conduct sequential vaccination research with the existing inactivated vaccine. After these studies are completed, it can be used, "this process will take a long time."

according to the latest data released by the national health and Health Committee 23, as of 22, the national total of 1 billion 947 million doses of COVID-19 vaccine has been reported. The single day vaccination rate is 11 million 85 thousand times, and the speed has slowed down. Zhang Yuntao told the Global Times reporter that on the whole, the vaccination rate for people over the age of 18 has been relatively high, but some of them have not been widely vaccinated. If there are people with diabetes, hypertension and immunodeficiency diseases, the number of these people is relatively large. At present, China biology is also stepping up clinical trials for the above-mentioned people, striving to achieve "all connections" as soon as possible < p > at the same time, accelerating the vaccination of minors is also considered to be an important part of building an immune barrier. Previously, the inactivated vaccines of China biology and Kexing have been approved to vaccinate people aged 3-17 years. Recently, all localities have begun to vaccinate people aged 12-17 years. According to Zhang Yuntao, from the clinical trials and current vaccination data, the vaccine is very safe. Zhang Yuntao believes that vaccination should be strengthened for this population, because most of them are students, and the school staff are relatively gathered, so it is very important to provide protection for them < p > the reporter of the global times also learned from China biology that on June 29 this year, the world's largest new crown vaccine production base of China biology was officially completed and put into operation. Up to now, the overall annual production capacity of China's new biological crown vaccine has exceeded 5 billion doses